TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Treatment of Iron Deficiency in IBD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Non-anaemic patients treated in the FERGI-CORRECTION study (Hb ≥12 g/dL female, ≥13 g/dL male), independent of ferritin value.~Females of child-bearing potential must have a negative urine pregnancy test at screening and be practising an acceptable method of birth control during the study and for up to 1 month after the last dose of study medication.~Exclusion Criteria:~Chronic alcohol abuse (alcohol consumption \>20 g/day).~Presence of portal hypertension with oesophageal varices. History of erythropoietin, intravenous or oral iron therapy, or blood transfusion in 12 weeks prior to screening.~Known hypersensitivity to FERINJECT®.~History of acquired iron overload.~Myelodysplastic syndrome.~Pregnancy or lactation.~Known active infection, clinically significant overt bleeding, active malignancy. Known chronic renal failure.~Surgery with relevant blood loss (defined as Hb drop \<2 g/dL) in the 3 months prior to screening or planned surgery within the following 3 months.~Chronic liver disease or increase of liver enzymes (alanine aminotransferase (\[ALT\], aspartate aminotransferase \[AST\]) \>3 times the upper limit of normal range.~Known human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.~Inability to fully comprehend and/or perform study procedures in the investigator's opinion.~Participation in any other interventional study (except correction study) within 1 month prior to screening.~Body weight \<35 kg.~Significant cardiovascular disease, including myocardial infarction within 12 months prior to study inclusion, congestive heart failure NYHA (New York Heart Association) grade III or IV, or poorly controlled hypertension according to the judgment of the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferinject (Type: EXPERIMENTAL): Intravenous infusion of iron
- Placebo (Type: PLACEBO_COMPARATOR): NaCL 0,9%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with a diagnosis of Alzheimer's disease according to the National Institute of Neurological and Communicative Disorders and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria (including patients living independently in residential homes for the elderly or day patients)~* have mild to moderate dementia, as evidenced by a, Mini-Mental Status Examination (MMSE) score of 11 - 24, and a score of at least 12 on the cognitive portion of the Alzheimer's Disease Assessment scale (ADAS-cog)~* history of at least 6 months of gradual and progressive cognitive decline~* have a consistent informant to accompany the patient on scheduled visits~Exclusion Criteria:~* Neurogenerative disorders such as Parkinson's disease~* dementia caused by small strokes or cerebrovascular disease~* cognitive impairment resulting from acute cerebral trauma, cerebral damage due to a lack of oxygen, vitamin deficiency, infections such as meningitis or AIDS, significant endocrine or metabolic disease, mental retardation or a brain tumor~* having epilepsy, significant psychiatric disease, active peptic ulcer, clinically significant liver, kidney or lung disorders or heart disease~* Females of child bearing potential without adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female patients aged ≥ 40 with stable moderate to severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines).~* Post-salbutamol Forced Expiratory Volume in one second(FEV1) \< 80% and ≥ 30% of predicted normal value and Post-salbutamol FEV1/Forced Vital Capacity (FVC) \< 70%.~* Current or ex-smokers of ≥ 10 pack-years~* Functional residual capacity (FRC) measured by body plethysmography at Screening Visit ≥ 120% of predicted value~Exclusion Criteria:~* History or current diagnosis of asthma~* Signs of an exacerbation within 6 weeks ( or 3 months if results in hospitalisation) prior to the screening visit or during the run-in period.~* Clinically significant respiratory and/or cardiovascular conditions or laboratory abnormalities.~* Conditions where the use of anticholinergic drugs is contraindicated, such as known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.~* Patients with an oxygen saturation \< 85% during cycle exercise on room air at Screening Visit, Run- in Visit and Visit 1.~* Contra-indications of cardiopulmonary exercise testing.~* Patient who in the investigator's opinion will need to start a pulmonary rehabilitation program during the study and/or patients who have just started/finished pulmonary rehabilitation at least 3 months prior to the Screening Visit.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aclidinium bromide (Type: EXPERIMENTAL): 3-week treatment periods
- Placebo (Type: EXPERIMENTAL): 3-week treatment periods

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 infected adults (=/+18 years old).~2. Patient having a diagnosis of HIV infection, on stable HAART including 2 NRTI/NtRTIs plus one of the following: 1 PI/ritonavir or ATV/unboosted or 1 NNRTI.~3. Undetectable plasma HIV-1 RNA (VL \< 50 copies/mL) while on HAART.~4. Patient having at least one of the following conditions:~   * Antiretroviral-related gastrointestinal disturbances, or~  * Low patient's satisfaction associated with the current regimen posology (ritonavir use, ritonavir intolerance...), or~  * Any toxicity drug related.~5. Nadir CD4 cell count \> 350 cells/mm3.~6. Absence of resistance mutations in the RT or PR by (TrugeneTM)~7. Good treatment adherence.~8. Voluntary written informed consent.~Exclusion Criteria:~1. Virologic failure to a previous antiretroviral regimen.~2. Any antiretroviral resistance mutation in a previous resistance test.~3. Dual/mixed or X4 viruses detected at any time point, including the pre-treatment ES-Trofile test of the PBMC test done before treatment switch.~4. Acute infections or uncontrolled chronic infection in the 2 months previous to the inclusion.~5. Pregnancy or fertile women willing to be pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- to switch from the NNRTI/PI to maraviroc (Type: EXPERIMENTAL): to switch from the NNRTI/PI to maraviroc
- to continue with the same approach (Type: ACTIVE_COMPARATOR): to continue with the same approach

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duloxetine for Pain in Older Adults With Knee Osteoarthritis (OA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* primary knee osteoarthritis~Exclusion Criteria:~* inflammatory conditions~* autoimmune disorders~* psychiatric illness~* morbid obesity

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Have a photo ID~2. Age\>18 years old (required to provide informed consent)~3. Age \<60 years old~4. Mild impairment of endothelial function, assessed by post ischemic vasodilation (L_RHI,\<0.7) (38)~5. Body mass index (BMI) \>27 kg/m\^2 and \<40 kg/m\^2~6. Fasting during the days of transfusion.~7. Avoiding intake of high nitrate food (i.e. green leafy vegetables: lettuce, spinach) on the day prior to the study~8. Feel well on the day of blood donation~9. KG within normal limits~10. Normotensive (systolic blood pressure \<140 mmHg and diastolic \<90 mmHg)~11. Normal physical exam and blood test results as indicated by:~    1. WBC 4.5-11.0 n x103/μL~   2. HGB 12.0-17.5 gm/dl~   3. PLT 150-400 n x103/μL~   4. Plasma Sodium 135-145 mmol/L~   5. Plasma Potassium 3.4-4.8 mmol/L~   6. Plasma Chloride 98-108 mmol/L~   7. Plasma Carbon Dioxide 23.0-31.9 mmol/L~   8. Plasma Urea Nitrogen 8-25 mg/dl~   9. Plasma Creatinine 0.60-1.50 mg/dl~   10. Plasma Glucose 70-110 mg/dl~   11. Transaminase-SGPT 10-55 U/L~   12. Transaminase-SGOT 10-40 U/L~   13. Total Bilirubin \< 2 mg/dl~   14. Fasting plasma glucose \< 110 mg/dl~   15. Methemoglobin \< 3%~Exclusion Criteria:~1. Psychiatric disturbances such as anxiety, depression, schizophrenia requiring pharmacological treatment or hospitalization in the last year~2. Systemic disease with or without any functional limitation~3. Pregnancy determined by urine pregnancy test, detecting presence of human chorionic gonadotropin (hCG), or less than six weeks postpartum~4. Active smoking. Volunteers may be enrolled if they quit smoking for more than 1 year.~5. Excess alcohol use: more than ½ L/day of wine consumption or equivalent~6. Any current use of a medication other than: over-the-counter oral medications, herbal remedies, nutritional supplements, and oral contraceptives.~7. Antibiotic use within 48 hours of blood donation~8. Use of NSAIDS, corticosteroids, aspirin during the past 7 days~9. Dental work within 24 hours prior to the donation~10. Received or donated blood in the last 4 months~11. Have had any forms of cancer with the exceptions of basal cell skin cancer or treatment for in situ uterine cervical cancer~12. Currently enrolled in another research study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Fresh blood (Type: EXPERIMENTAL): None
- Old blood (Type: EXPERIMENTAL): None
- Old blood + inhaled Nitric Oxide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TAF for HIV-HBV With Renal Dysfunction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV/HBV-coinfection~* Suppressed HIV-viremia (\<200 cp/ml)~* On TDF-containing ART since at least 6 months~* eGFR \> 30 ml/min and \<90 ml/min~* Written informed consent~Exclusion Criteria:~* Study drug considered by the treating physician not a valid option for the patient~* Pregnancy~* Decompensated liver cirrhosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Switch (Type: EXPERIMENTAL): Patients are switched from a TDF-containing antiretroviral therapy regimen to a TAF-containing regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects of Chinese descent with full Chinese parentage.~* Diagnosis of Crohn's disease (CD) for at least 3 months prior to Week 0.~* Crohn's Disease Activity Index (CDAI) greater than or equal to 220 and less than or equal to 450 despite treatment with oral corticosteroids and/or immunosuppressants.~* Subject has a negative Tuberculosis (TB) Screening Assessment.~* Subject has elevated high sensitivity C-reactive protein (hs-CRP) during the Screening Period.~Exclusion Criteria:~* Subject with ulcerative colitis or indeterminate colitis.~* Subject who has had a surgical bowel resection within the past 6 months or who is planning any resection at any time point in the future.~* Subject with an ostomy or ileoanal pouch.~* Subject who has short bowel syndrome.~* Subject with symptomatic known obstructive strictures.~* Subject with an internal or external fistula (with the exception of an anal fistula without abscess).~* Active, or chronic or recurring infections, or active tuberculosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Induction Regimen (Type: EXPERIMENTAL): Double-blind period (Weeks 0-8): Placebo at Weeks 0 and 2, followed by adalimumab 160 mg at Week 4, 80 mg at Week 6.~Open label period: adalimumab 40 mg every other week (eow) from Week 8 through last dose at Week 24.
- Adalimumab Induction Regimen (Type: EXPERIMENTAL): Double-blind period (Weeks 0-8): adalimumab 160 mg at Weeks 0 and 80 mg at Week 2, followed by adalimumab 40 mg at Week 4 and Week 6.~Open label period: adalimumab 40 mg eow from Week 8 through last dose at Week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Effectiveness of Levofloxacin Compared With Ciprofloxacin in Patients With Chronic Bacterial Prostatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic prostatitis meeting all 3 of the following criteria: 1) clinical signs and symptoms of prostatitis including tender prostate and one or more of the following: difficulty in, frequency of, or urgency of urinating, retention of urine or hesitancy in urinating, decreased urinary stream, painful ejaculation, pelvic or low back pain, pain on examination, fever or chills~* 2) history of chronic prostatitis defined as 1 previous episode lasting 4 weeks or 2 or more episodes during the previous 12 months~* And 3) laboratory evidence of prostatitis~* Able to take oral medications~* Over-the-counter medications for chronic prostatitis are continued at the same dose during the study or are discontinued before study entry~Exclusion Criteria:~* Have taken an antibiotic similar to levofloxacin for any reason within the past 14 days~* Have received any medication for more than 24 hours during the past 7 days that may be effective in treating prostatitis unless there is evidence of treatment failure after 5 or more days of treatment with the other medication~* Have had certain surgeries during the past 6 months, including prostate surgery, surgical opening of the bladder or kidney or insertion of a permanent catheter (tube) for urination~* Taking any medications that may affect bladder or prostate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Mircera for the Maintenance Treatment of Participants With Chronic Renal Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults greater than or equal to (≥) 18 years of age~* Chronic renal anemia~* Stable epoetin alfa or darbepoetin alfa therapy for past 2 months~* Hemodialysis therapy for ≥3 months~Exclusion Criteria:~* Transfusion of red blood cells during previous 2 months~* Poorly controlled hypertension requiring hospitalization or interruption of ESA treatment in previous 6 months~* Acute or chronic bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mircera in Renal Anemia (Type: EXPERIMENTAL): Participants with chronic renal anemia who have been previously treated with erythropoiesis-stimulating agent (ESA) therapy will receive IV Mircera every 4 weeks for a total of 24 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment. Subsequent doses will be adjusted to maintain Hb concentrations within target of 10.5 and 12.5 grams per deciliter (g/dL).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telaprevir Open-Label Study in Co-Infected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria: - Have diagnosis of HIV-1 or HIV-2 infection, or HIV-1 and HIV-2 coinfection for more than 6 months before the screening visit. - Should have been on a stable permissible HAART regimen for more than 8 weeks before Day 1 without switches. OR Not on a HAART regimen and not expected to start HIV treatment during the study, ie, have CD4 count of ≥500 cells/mm3 and a HIV-1 and/or HIV-2 viral load ≤50,000 copies/mL at screening - If on stable permissible HAART regimen, have CD4 count ≥200 cells/mm3 or ≥15% and HIV-1 and/or HIV-2 viral load \<50 copies/mL for at least 6 months before starting treatment is recommended - Have evidence of HCV infection genotype 1 (molecular assay) - Have a quantifiable plasma HCV RNA Exclusion Criteria: - Is eligible for enrollment into an ongoing clinical study of telaprevir - Is infected or coinfected with HCV of another genotype than genotype 1 - Has a contraindication to the administration of Peg-IFN-alfa or RBV, or medical history or laboratory values that preclude treatment with Peg-IFN-alfa or RBV according to the respective local prescribing information - Have any contraindication to the currently prescribed HAART regimen at screening. Note: Patients who have a contraindication to a nonprescribed permissible HAART medication are not excluded. - Positive human leukocyte antigen (HLA)-B5701 genotyping result at screening (or documented result prior to screening) if abacavir is a component of HAART

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- open label telaprevir (Type: EXPERIMENTAL): Depending on the patient's HAART regimen, 750 or 1125 mg telaprevir every 8 hours for 12 weeks in combination with pegylated interferon alfa and ribavirin for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete